Anosmia

Last updated
Anosmia
Other namesLoss of smell, smell blindness, [1] odor blindness
Anosmia.jpg
Inflamed nasal mucosa causing anosmia
Pronunciation
Specialty Otorhinolaryngology
TypesPartial, total [2]

Anosmia, also known as smell blindness, is the loss of the ability to detect one or more smells. [1] [2] Anosmia may be temporary or permanent. [3] It differs from hyposmia, which is a decreased sensitivity to some or all smells. [2]

Contents

Anosmia can be categorized into acquired anosmia and congenital anosmia. Acquired anosmia develops later in life due to various causes, such as upper respiratory infections, head trauma, or neurodegenerative diseases. [4] In contrast, congenital anosmia is present from birth and is typically caused by genetic factors or developmental abnormalities of the olfactory system. [5] While acquired anosmia may have potential treatments depending on the underlying cause, such as medications or surgery, congenital anosmia currently has no known cure, and management focuses on safety precautions and coping strategies. [6]

Anosmia can be due to a number of factors, including inflammation of the nasal mucosa, blockage of nasal passages, or destruction of temporal lobular tissue. [7] Anosmia stemming from sinus inflammation is due to chronic mucosal changes in the lining of the paranasal sinus and in the middle and superior turbinates. [8] [9]

When anosmia is caused by inflammatory changes in the nasal passageways, it is treated simply by reducing inflammation. [10] [11] It can be caused by chronic meningitis and neurosyphilis that would increase intracranial pressure over a long period of time, [12] and, in some cases, by ciliopathy, [13] including ciliopathy due to primary ciliary dyskinesia. [14]

The term derives from the Neo-Latin anosmia, based on Ancient Greek ἀν- (an-) + ὀσμή (osmḗ 'smell'; another related term, hyperosmia, refers to an increased ability to smell). Some people may be anosmic for one particular odor, a condition known as "specific anosmia". The absence of the sense of smell from birth is known as congenital anosmia. [15]

In the United States, 3% of people aged over 40 are affected by anosmia. [3]

Anosmia is a common symptom of COVID-19 and can persist as long COVID. [16]

Definition

Anosmia is the inability to smell. [1] It may be partial or total, and can be specific to certain smells. [2] Reduced sensitivity to some or all smells is hyposmia. [2]

Signs and symptoms

Anosmia can have a number of harmful effects. [17] People with sudden onset anosmia may find food less appetizing, though congenital anosmics rarely complain about this, and none report a loss in weight. Loss of smell can also be dangerous because it hinders the detection of gas leaks, fire, and spoiled food. Misconceptions of anosmia as trivial can make it more difficult for a patient to receive the same types of medical aid as someone who has lost other senses, such as hearing or sight.[ citation needed ]

Many experience one sided loss of smell, often as a result of minor head trauma. This type of anosmia is normally only detected if both of the nostrils are tested separately. Using this method of testing each nostril separately will often show a reduced or even completely absent sense of smell in either one nostril or both, something which is often not revealed if both nostrils are simultaneously tested. [18]

Losing an established and sentimental smell memory (e.g. the smell of grass, of the grandparents' attic, of a particular book, of loved ones, or of oneself) has been known to cause feelings of depression. [19] [ better source needed ]

Loss of the ability to smell may lead to the loss of libido, but this usually does not apply to those with olfactory dysfunction at birth. [19] [20]

Often people who have loss of smell at birth report that they pretended to be able to smell as children because they thought that smelling was something that older/mature people could do, or did not understand the concept of smelling but did not want to appear different from others. When children get older, they often realize and report to their parents that they do not actually possess a sense of smell, often to the surprise of their parents.[ citation needed ]

Causes

A temporary loss of smell can be caused by a blocked nose or infection. In contrast, a permanent loss of smell may be caused by death of olfactory receptor neurons in the nose or by brain injury in which there is damage to the olfactory nerve or damage to brain areas that process smell (see olfactory system). The lack of the sense of smell at birth, usually due to genetic factors, is referred to as congenital anosmia. Family members of the patient with congenital anosmia are often found with similar histories; this suggests that the anosmia may follow an autosomal dominant pattern. [21] Anosmia may very occasionally be an early sign of a degenerative brain disease such as Parkinson's disease and Alzheimer's disease.[ citation needed ]

Another specific cause of permanent loss could be from damage to olfactory receptor neurons because of use of certain types of nasal spray; i.e., those that cause vasoconstriction of the nasal microcirculation. To avoid such damage and the subsequent risk of loss of smell, vasoconstricting nasal sprays should be used only when absolutely necessary and then for only a short amount of time. Non-vasoconstricting sprays, such as those used to treat allergy-related congestion, are safe to use for prescribed periods of time. [22] Anosmia can also be caused by nasal polyps. These polyps are found in people with allergies, histories of sinusitis, and family history. Individuals with cystic fibrosis often develop nasal polyps.[ citation needed ]

Amiodarone is a drug used in the treatment of arrhythmias of the heart. A clinical study demonstrated that the use of this drug induced anosmia in some patients. Although rare, there was a case in which a 66-year-old male was treated with amiodarone for ventricular tachycardia. After the use of the drug he began experiencing olfactory disturbance, however after decreasing the dosage of amiodarone, the severity of the anosmia decreased accordingly, suggesting a relationship between use of amiodarone to the development of anosmia. [23]

Chemosensory disturbances, including loss of smell or taste, are the predominant neurological symptom of COVID-19. [24] [25] As many as 80% of COVID-19 patients exhibit some change in chemesthesis, including smell. Loss of smell has also been found to be more predictive of COVID-19 than all other symptoms, including fever, cough, or fatigue, based on a survey of 2 million participants in the UK and US. [26] Google searches for "smell", "loss of smell", "anosmia", and other similar terms increased since the early months of the pandemic, and strongly correlated with increases in daily cases and deaths. [27] Research into the mechanisms underlying these symptoms is currently ongoing. [28] [29]

Many countries list anosmia as an official COVID-19 symptom, and some have developed "smell tests" as potential screening tools. [30] [31]

In 2020, the Global Consortium for Chemosensory Research, a collaborative research organization of international smell and taste researchers, formed to investigate loss of smell and related chemosensory symptoms. [32]

Decision-making in COVID-19 patients

Studies have indicated that patients who presented with anosmia during the acute phase of COVID-19 are more likely to develop changes in decision-making, exhibiting more impulsive responses, which are associated with functional and structural brain changes. [33]

Possible causes

Diagnosis

Diagnosis begins with a detailed history, including possible related injuries, such as upper respiratory infections or head injury. The examination may involve nasal endoscopy for obstructive factors such as polyps or swelling. [7] A nervous system examination is performed to see if the cranial nerves are affected. [7] On occasion, after head traumas, there are people who have unilateral anosmia. The sense of smell should be tested individually in each nostril. [18]

Many cases of congenital anosmia remain unreported and undiagnosed. Since the disorder is present from birth the individual may have little or no understanding of the sense of smell, hence is unaware of the deficit. [55] It may also lead to reduction of appetite. [56]

Treatment

Though anosmia caused by brain damage cannot be treated, anosmia caused by inflammatory changes in the mucosa may be treated with glucocorticoids. Reduction of inflammation through the use of oral glucocorticoids such as prednisone, followed by long term topical glucocorticoid nasal spray, would easily and safely treat the anosmia. A prednisone regimen is adjusted based on the degree of the thickness of mucosa, the discharge of oedema and the presence or absence of nasal polyps. [10] However, the treatment is not permanent and may have to be repeated after a short while. [10] Together with medication, pressure of the upper area of the nose must be mitigated through aeration and drainage. [57]

Anosmia caused by a nasal polyp may be treated by steroidal treatment or removal of the polyp. [58]

Although very early in development, gene therapy has restored a sense of smell in mice with congenital anosmia when caused by ciliopathy. In this case, a genetic condition had affected cilia in their bodies which normally enabled them to detect air-borne chemicals, and an adenovirus was used to implant a working version of the IFT88 gene into defective cells in the nose, which restored the cilia and allowed a sense of smell. [59] [60]

Epidemiology

In the United States, 3% of people aged over 40 are affected by anosmia. [3]

In 2012, smell was assessed in persons aged 40 years and older with rates of anosmia/severe hyposmia of 0.3% at age 40–49 rising to 14.1% at age 80+. Rates of hyposmia were much higher: 3.7% at age 40–49 and 25.9% at 80+. [61]

Famous people with anosmia

See also

Related Research Articles

Dysgeusia, also known as parageusia, is a distortion of the sense of taste. Dysgeusia is also often associated with ageusia, which is the complete lack of taste, and hypogeusia, which is a decrease in taste sensitivity. An alteration in taste or smell may be a secondary process in various disease states, or it may be the primary symptom. The distortion in the sense of taste is the only symptom, and diagnosis is usually complicated since the sense of taste is tied together with other sensory systems. Common causes of dysgeusia include chemotherapy, asthma treatment with albuterol, and zinc deficiency. Liver disease, hypothyroidism, and rarely, certain types of seizures can also lead to dysgeusia. Different drugs can also be responsible for altering taste and resulting in dysgeusia. Due to the variety of causes of dysgeusia, there are many possible treatments that are effective in alleviating or terminating the symptoms. These include artificial saliva, pilocarpine, zinc supplementation, alterations in drug therapy, and alpha lipoic acid.

<span class="mw-page-title-main">Nasal cavity</span> Large, air-filled space above and behind the nose in the middle of the face

The nasal cavity is a large, air-filled space above and behind the nose in the middle of the face. The nasal septum divides the cavity into two cavities, also known as fossae. Each cavity is the continuation of one of the two nostrils. The nasal cavity is the uppermost part of the respiratory system and provides the nasal passage for inhaled air from the nostrils to the nasopharynx and rest of the respiratory tract.

<span class="mw-page-title-main">Olfactory system</span> Sensory system used for smelling

The olfactory system, or sense of smell, is the sensory system used for olfaction. Olfaction is one of the special senses directly associated with specific organs. Most mammals and reptiles have a main olfactory system and an accessory olfactory system. The main olfactory system detects airborne substances, while the accessory system senses fluid-phase stimuli.

Kallmann syndrome (KS) is a genetic disorder that prevents a person from starting or fully completing puberty. Kallmann syndrome is a form of a group of conditions termed hypogonadotropic hypogonadism. To distinguish it from other forms of hypogonadotropic hypogonadism, Kallmann syndrome has the additional symptom of a total lack of sense of smell (anosmia) or a reduced sense of smell. If left untreated, people will have poorly defined secondary sexual characteristics, show signs of hypogonadism, almost invariably are infertile and are at increased risk of developing osteoporosis. A range of other physical symptoms affecting the face, hands and skeletal system can also occur.

<span class="mw-page-title-main">Aspirin-exacerbated respiratory disease</span> Chronic inflammatory disease affecting the sinuses and lungs

Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Compared to aspirin tolerant patients, AERD patients' asthma and nasal polyps are generally more severe. Reduction or loss of the ability to smell is extremely common, occurring in more than 90% of people with the disease. AERD most commonly begins in early- to mid-adulthood and has no known cure. While NSAID intolerance is a defining feature of AERD, avoidance of NSAIDs does not affect the onset, development or perennial nature of the disease.

Ageusia is the loss of taste functions of the tongue, particularly the inability to detect sweetness, sourness, bitterness, saltiness, and umami. It is sometimes confused with anosmia – a loss of the sense of smell. True ageusia is relatively rare compared to hypogeusia – a partial loss of taste – and dysgeusia – a distortion or alteration of taste.

Parosmia is a dysfunctional smell detection characterized by the inability of the brain to correctly identify an odor's "natural" smell. Instead, the natural odor is usually transformed into an unpleasant aroma, typically a "burned", "rotting", "fecal", or "chemical" smell. There can also be rare instances of a pleasant odor called euosmia. The condition was rare and little-researched until it became relatively more widespread since 2020 as a side effect of COVID-19.

Phantosmia, also called an olfactory hallucination or a phantom odor, is smelling an odor that is not actually there. This is intrinsically suspicious as the formal evaluation and detection of relatively low levels of odour particles is itself a very tricky task in air epistemology. It can occur in one nostril or both. Unpleasant phantosmia, cacosmia, is more common and is often described as smelling something that is burned, foul, spoiled, or rotten. Experiencing occasional phantom smells is normal and usually goes away on its own in time. When hallucinations of this type do not seem to go away or when they keep coming back, it can be very upsetting and can disrupt an individual's quality of life.

Hyposmia, or microsmia, is a reduced ability to smell and to detect odors. A related condition is anosmia, in which no odors can be detected. Some of the causes of olfaction problems are allergies, nasal polyps, viral infections and head trauma. In 2012 an estimated 9.8 million people aged 40 and older in the United States had hyposmia and an additional 3.4 million had anosmia/severe hyposmia.

Hypogeusia can be defined as the reduced ability to taste things. Due to a lack of stratification, the prevalence of hypogeusia, as well as hyposmia, may not be accurately known. Additionally, reviews do not always make distinctions between ageusia and hypogeusia, often classifying them as the same in certain circumstances and studies. The severity of the loss of taste from hypogeusia is not clearly outlined in current research due to these reasons.

Dysosmia is a disorder described as any qualitative alteration or distortion of the perception of smell. Qualitative alterations differ from quantitative alterations, which include anosmia and hyposmia. Dysosmia can be classified as either parosmia or phantosmia. Parosmia is a distortion in the perception of an odorant. Odorants smell different from what one remembers. Phantosmia is the perception of an odor when no odorant is present. The cause of dysosmia still remains a theory. It is typically considered a neurological disorder and clinical associations with the disorder have been made. Most cases are described as idiopathic and the main antecedents related to parosmia are URTIs, head trauma, and nasal and paranasal sinus disease. Dysosmia tends to go away on its own but there are options for treatment for patients that want immediate relief.

<span class="mw-page-title-main">Sense of smell</span> Sense that detects smells

The sense of smell, or olfaction, is the special sense through which smells are perceived. The sense of smell has many functions, including detecting desirable foods, hazards, and pheromones, and plays a role in taste.

Many types of sense loss occur due to a dysfunctional sensation process, whether it be ineffective receptors, nerve damage, or cerebral impairment. Unlike agnosia, these impairments are due to damages prior to the perception process.

The University of Pennsylvania Smell Identification Test (UPSIT) is a test that is commercially available for smell identification to test the function of an individual's olfactory system.

<span class="mw-page-title-main">Anosmia Awareness Day</span> Day to spread awareness about individuals who lose sense of smell

Anosmia Awareness Day is a day to spread awareness about anosmia (an-OHZ-me-uh), the loss of the sense of smell. It takes place each year on February 27.

<span class="mw-page-title-main">Symptoms of COVID-19</span>

The symptoms of COVID-19 are variable depending on the type of variant contracted, ranging from mild symptoms to a potentially fatal illness. Common symptoms include coughing, fever, loss of smell (anosmia) and taste (ageusia), with less common ones including headaches, nasal congestion and runny nose, muscle pain, sore throat, diarrhea, eye irritation, and toes swelling or turning purple, and in moderate to severe cases, breathing difficulties. People with the COVID-19 infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; and a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea. In people without prior ear, nose, or throat disorders, loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 88% of symptomatic cases.

Claire Hopkins is a British Ear, Nose & Throat (ENT) surgeon at Guy's Hospital and Professor of Rhinology at King's College London. She is the President of the British Rhinological Society. During the COVID-19 pandemic, Hopkins successfully campaigned to have anosmia recognised as a symptom of COVID-19 in the United Kingdom.

<span class="mw-page-title-main">Impact of COVID-19 on neurological, psychological and other mental health outcomes</span>

There is increasing evidence suggesting that COVID-19 causes both acute and chronic neurologicalor psychological symptoms. Caregivers of COVID-19 patients also show a higher than average prevalence of mental health concerns. These symptoms result from multiple different factors.

Smell training or olfactory training is the act of regularly sniffing or exposing oneself to robust aromas with the intention of regaining a sense of smell. The stimulating smells used are often selected from major smell categories, such as aromatic, flowery, fruity, and resinous. Using strong scents, the patient is asked to sniff each different smell for a minimum of 20 seconds, no less than two times per day, for three to six months or more. It is used as a rehabilitative therapy to help people who have anosmia or post-viral olfactory dysfunction, a symptom of COVID-19. It was considered a promising experimental treatment in a 2017 meta-analysis.

<span class="mw-page-title-main">Congenital anosmia</span> Medical condition

Congenital anosmia is a rare condition characterized by the complete inability to perceive smell from birth. It affects approximately 1 in 10,000 individuals and is often diagnosed later in life due to its subtle presentation and lack of associated symptoms.

References

  1. 1 2 3 Coon D, Mitterer J (2014). "4. Sensation and perception". Introduction to Psychology: Gateways to Mind and Behavior. Boston: Cengage Learning. p. 136. ISBN   978-1-305-09187-0. LCCN   2014942026.
  2. 1 2 3 4 5 Jones N (2010). "2. Making sense of symptoms". In Jones N (ed.). Practical Rhinology. CRC Press. pp. 24–25. ISBN   978-1-4441-0861-3.
  3. 1 2 3 4 Li X, Lui F (6 July 2020). "Anosmia". StatPearls. StatPearls Publishing. PMID   29489163 . Retrieved 1 December 2020.
  4. Li, X.; Lui, F. (2021). "Anosmia - StatPearls - NCBI Bookshelf". NCBI. PMID   29489163 . Retrieved 2024-07-06.
  5. "Congenital Anosmia". Fifth Sense. Retrieved 2024-07-06.
  6. "Loss of smell (anosmia) Causes". Mayo Clinic. Retrieved 2024-07-06.
  7. 1 2 3 Huynh PP, Ishii LE, Ishii M (July 2020). "What Is Anosmia?". JAMA. 324 (2): 206. doi: 10.1001/jama.2020.10966 . PMID   32556300. S2CID   219916772.
  8. Helliwell T (June 2010). "Inflammatory diseases of the nasal cavities and paranasal sinuses". Diagnostic Histopathology. 16 (6): 255–264. doi:10.1016/j.mpdhp.2010.03.008. PMC   7172334 . PMID   32336992.
  9. Lin YT, Yeh TH (2022). "Studies on Clinical Features, Mechanisms, and Management of Olfactory Dysfunction Secondary to Chronic Rhinosinusitis". Frontiers in Allergy. 3: 835151. doi: 10.3389/falgy.2022.835151 . PMC   8974686 . PMID   35386650.
  10. 1 2 3 Knight A (August 1988). "Anosmia". Lancet. 2 (8609): 512. doi:10.1016/s0140-6736(88)90160-2. PMID   2900434. S2CID   208793859.(subscription required)
  11. "Sinusitis Clinical Practice Guideline Quick Reference Tools", Pediatric Clinical Practice Guidelines & Policies, American Academy of Pediatrics, pp. 481–484, 2022-04-11, doi:10.1542/9781610026086-part01-27, ISBN   978-1-61002-608-6 , retrieved 2023-11-07
  12. "Anosmia". The Lancet. 241 (6228): 55. 1943. doi:10.1016/S0140-6736(00)89085-6. S2CID   241387103.
  13. Uytingco CR, Green WW, Martens JR (2019). "Olfactory Loss and Dysfunction in Ciliopathies: Molecular Mechanisms and Potential Therapies". Current Medicinal Chemistry. 26 (17): 3103–3119. doi:10.2174/0929867325666180105102447. PMC   6034980 . PMID   29303074.
  14. Ul Hassan A, Hassan G, Khan SH, Rasool Z, Abida A (January 2009). "Ciliopathy with special emphasis on kartageners syndrome". International Journal of Health Sciences. 3 (1): 65–69. PMC   3068795 . PMID   21475513.
  15. Boesveldt S, Postma EM, Boak D, Welge-Luessen A, Schöpf V, Mainland JD, et al. (September 2017). "Anosmia-A Clinical Review". Chemical Senses. 42 (7): 513–523. doi:10.1093/chemse/bjx025. PMC   5863566 . PMID   28531300.
  16. "Q&A: COVID-19 and loss of smell, taste". Mayo Clinic Health System. Retrieved 2022-02-23.
  17. Toller SV (December 1999). "Assessing the impact of anosmia: review of a questionnaire's findings". Chemical Senses. 24 (6): 705–712. doi: 10.1093/chemse/24.6.705 . PMID   10587505.
  18. 1 2 Harvey P (February 2006). "Anosmia". Practical Neurology . 6 (1): 65.
  19. 1 2 Heald C (December 27, 2006). "Sense and scent ability". BBC News. Retrieved April 25, 2010.
  20. Gudziol V, Wolff-Stephan S, Aschenbrenner K, Joraschky P, Hummel T (July 2009). "Depression resulting from olfactory dysfunction is associated with reduced sexual appetite--a cross-sectional cohort study". The Journal of Sexual Medicine. 6 (7): 1924–1929. doi:10.1111/j.1743-6109.2009.01266.x. PMID   19453919.
  21. Waguespack RW (1992). "Congenital Anosmia". Archives of Otolaryngology–Head & Neck Surgery. 118 (1): 10. doi:10.1001/archotol.1992.01880010012002.
  22. Preventing Anosmia from Intranasal Zinc Administration [ unreliable medical source? ]
  23. Maruyama T, Yasuda S, Odashiro K, Kaji Y, Harada M (November 2007). "Anosmia induced by amiodarone". The American Journal of Medicine. 120 (11): e9. doi: 10.1016/j.amjmed.2006.08.029 . PMID   17976411.
  24. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. (August 2020). "Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study". European Archives of Oto-Rhino-Laryngology. 277 (8): 2251–2261. doi: 10.1007/s00405-020-05965-1 . PMC   7134551 . PMID   32253535.
  25. Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, et al. (September 2020). "Smell and taste dysfunction in patients with COVID-19". The Lancet. Infectious Diseases. 20 (9): 1015–1016. doi: 10.1016/S1473-3099(20)30293-0 . PMC   7159875 . PMID   32304629.
  26. Menni C, Valdes AM, Freidin MB, et al. (July 2020). "Real-time tracking of self-reported symptoms to predict potential COVID-19". Nature Medicine. 26 (7): 1037–1040. doi: 10.1038/s41591-020-0916-2 . PMC   7751267 . PMID   32393804.
  27. Walker A, Hopkins C, Surda P (July 2020). "Use of Google Trends to investigate loss-of-smell-related searches during the COVID-19 outbreak". International Forum of Allergy & Rhinology. 10 (7): 839–847. doi: 10.1002/alr.22580 . PMC   7262261 . PMID   32279437.
  28. Shelton, J. F., Shastri, A. J., Fletez-Brant, K., Aslibekyan, S., & Auton, A. (2022). The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste. Nature Genetics, 54(2), 121-124.
  29. Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al. (July 2020). "COVID-19 and the Chemical Senses: Supporting Players Take Center Stage". Neuron. 107 (2): 219–233. doi: 10.1016/j.neuron.2020.06.032 . PMC   7328585 . PMID   32640192.
  30. Iravani B, Arshamian A, Ravia A, Mishor E, Snitz K, Shushan S, et al. (11 May 2020). "Relationship between odor intensity estimates and COVID-19 population prediction in a Swedish sample". medRxiv   10.1101/2020.05.07.20094516 .
  31. Rodriguez S, Cao L, Rickenbacher GT, Benz EG, Magdamo C, Ramirez Gomez LA, et al. (June 2020). "Innate immune signaling in the olfactory epithelium reduces odorant receptor levels: modeling transient smell loss in COVID-19 patients". medRxiv   10.1101/2020.06.14.20131128 .
  32. "Global Consortium for Chemosensory Research". Global Consortium for Chemosensory Research (GCCR). Retrieved 10 July 2020.
  33. Kausel, L. (2024). "Patients recovering from COVID-19 who presented with anosmia during their acute episode have behavioral, functional, and structural brain alterations". Scientific Reports. 14 (1): 19049. doi:10.1038/s41598-024-69772-y. PMC   11329703 . PMID   39152190 . Retrieved 24 October 2024.
  34. Doty RL, Mishra A (March 2001). "Olfaction and its alteration by nasal obstruction, rhinitis, and rhinosinusitis". The Laryngoscope. 111 (3): 409–423. doi:10.1097/00005537-200103000-00008. PMC   7165948 . PMID   11224769.
  35. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade RG (23 June 2020). "The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries". PLOS ONE. 15 (6): e0234765. Bibcode:2020PLoSO..1534765G. doi: 10.1371/journal.pone.0234765 . PMC   7310678 . PMID   32574165.
  36. "Coronavirus Disease 2019 (COVID-19) – Symptoms". Centers for Disease Control and Prevention. 13 May 2020. Retrieved 14 May 2020.
  37. Ta NH (January 2019). "Will we ever cure nasal polyps?". Annals of the Royal College of Surgeons of England. 101 (1): 35–39. doi:10.1308/rcsann.2018.0149. PMC   6303820 . PMID   30286644.
  38. Doty RL, Yousem DM, Pham LT, Kreshak AA, Geckle R, Lee WW (September 1997). "Olfactory dysfunction in patients with head trauma". Archives of Neurology. 54 (9): 1131–1140. doi:10.1001/archneur.1997.00550210061014. PMID   9311357.
  39. National Research Council (US) Committee on Emergency and Continuous Exposure Guidance Levels for Selected Submarine Contaminants (2009). Hydrogen Sulfide. National Academies Press (US).
  40. Doty RL, Deems DA, Stellar S (August 1988). "Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration". Neurology. 38 (8): 1237–1244. doi:10.1212/WNL.38.8.1237. PMID   3399075. S2CID   3009692.
  41. Murphy C (April 1999). "Loss of olfactory function in dementing disease". Physiology & Behavior. 66 (2): 177–182. doi:10.1016/S0031-9384(98)00262-5. PMID   10336141. S2CID   26110446.
  42. Schwartz BS, Doty RL, Monroe C, Frye R, Barker S (May 1989). "Olfactory function in chemical workers exposed to acrylate and methacrylate vapors". American Journal of Public Health. 79 (5): 613–618. doi:10.2105/AJPH.79.5.613. PMC   1349504 . PMID   2784947.
  43. Rose CS, Heywood PG, Costanzo RM (June 1992). "Olfactory impairment after chronic occupational cadmium exposure". Journal of Occupational Medicine. 34 (6): 600–605. PMID   1619490.
  44. Rydzewski B, Sułkowski W, Miarzyńska M (1998). "Olfactory disorders induced by cadmium exposure: a clinical study". International Journal of Occupational Medicine and Environmental Health. 11 (3): 235–245. PMID   9844306.
  45. Doty RL, Shaman P, Applebaum SL, Giberson R, Siksorski L, Rosenberg L (December 1984). "Smell identification ability: changes with age". Science. 226 (4681): 1441–1443. Bibcode:1984Sci...226.1441D. doi:10.1126/science.6505700. PMID   6505700.
  46. Somenek M (October 30, 2009). Harris JE (ed.). "Esthesioneuroblastoma". eMedicine .
  47. Seo BS, Lee HJ, Mo JH, Lee CH, Rhee CS, Kim JW (October 2009). "Treatment of postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone nasal spray". Archives of Otolaryngology–Head & Neck Surgery. 135 (10): 1000–1004. doi: 10.1001/archoto.2009.141 . PMID   19841338.
  48. Rupp CI, Fleischhacker WW, Kemmler G, Kremser C, Bilder RM, Mechtcheriakov S, et al. (May 2005). "Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia". Schizophrenia Research. 74 (2–3): 149–161. doi:10.1016/j.schres.2004.07.010. PMID   15721995. S2CID   11026266.
  49. Kieff DA, Boey H, Schaefer PW, Goodman M, Joseph MP (December 1997). "Isolated neurosarcoidosis presenting as anosmia and visual changes". Otolaryngology–Head and Neck Surgery. 117 (6): S183–S186. doi:10.1016/S0194-5998(97)70097-4. PMID   9419143.
  50. Harris G (June 16, 2009). "F.D.A. Warns Against Use of Popular Cold Remedy". New York Times.
  51. Wheeler TT, Alberts MA, Dolan TA, McGorray SP (December 1995). "Dental, visual, auditory and olfactory complications in Paget's disease of bone". Journal of the American Geriatrics Society. 43 (12): 1384–1391. doi:10.1111/j.1532-5415.1995.tb06618.x. PMID   7490390. S2CID   26893932.
  52. Eriksen KD, Bøge-Rasmussen T, Kruse-Larsen C (June 1990). "Anosmia following operation for cerebral aneurysms in the anterior circulation". Journal of Neurosurgery. 72 (6): 864–865. doi:10.3171/jns.1990.72.6.0864. PMID   2338570.
  53. Leon-Sarmiento FE, Bayona EA, Bayona-Prieto J, Osman A, Doty RL (2012). "Profound olfactory dysfunction in myasthenia gravis". PLOS ONE. 7 (10): e45544. Bibcode:2012PLoSO...745544L. doi: 10.1371/journal.pone.0045544 . PMC   3474814 . PMID   23082113.
  54. Churchman A, O'Leary MA, Buckley NA, Page CB, Tankel A, Gavaghan C, et al. (December 2010). "Clinical effects of red-bellied black snake (Pseudechis porphyriacus) envenoming and correlation with venom concentrations: Australian Snakebite Project (ASP-11)". The Medical Journal of Australia. 193 (11–12): 696–700. doi:10.5694/j.1326-5377.2010.tb04108.x. PMID   21143062. S2CID   15915175.
  55. Vowles RH, Bleach NR, Rowe-Jones JM (August 1997). "Congenital anosmia". International Journal of Pediatric Otorhinolaryngology. 41 (2): 207–214. doi:10.1016/S0165-5876(97)00075-X. PMID   9306177.
  56. Sumner D (1971). "Appetite and Anosmia". The Lancet. 297 (7706): 970. doi:10.1016/S0140-6736(71)91470-X.
  57. Turnley WH (April 1963). "Anosmia". The Laryngoscope. 73 (4): 468–473. doi:10.1288/00005537-196304000-00012. PMID   13994924. S2CID   221921289.
  58. McClay JE (May 1, 2014). "Nasal Polyps Treatment & Management". Medscape .
  59. McIntyre JC, Davis EE, Joiner A, Williams CL, Tsai IC, Jenkins PM, et al. (September 2012). "Gene therapy rescues cilia defects and restores olfactory function in a mammalian ciliopathy model". Nature Medicine. 18 (9): 1423–1428. doi:10.1038/nm.2860. PMC   3645984 . PMID   22941275.
  60. Gallagher J (September 3, 2012). "Gene therapy restores sense of smell in mice". BBC News.
  61. Hoffman HJ, Rawal S, Li CM, Duffy VB (June 2016). "New chemosensory component in the U.S. National Health and Nutrition Examination Survey (NHANES): first-year results for measured olfactory dysfunction". Reviews in Endocrine & Metabolic Disorders. 17 (2): 221–240. doi:10.1007/s11154-016-9364-1. PMC   5033684 . PMID   27287364.
  62. Parker, Olivia (11 April 2016). "'My partner does "armpit duty"': What it's like to live with no sense of smell". The Telegraph. Retrieved 8 December 2018.
  63. "The Neglected Sense". BBC Radio 4. Retrieved 8 December 2018.
  64. DeGregory, Lane (30 November 2023). "For decades, a Florida woman had no sense of smell. Can she get it back?". Tampa Bay Times. Retrieved 2023-12-05.
  65. Sullivan, Justin (8 Apr 2021). "Ben & Jerry's' Ben Cohen Interview". Delish. Retrieved 6 Jan 2024.
  66. Izundu, Chi Chi (7 October 2013). "Little Mix's Perrie Edwards: I have no sense of smell - BBC Newsbeat". BBC News. Archived from the original on 8 November 2020. Retrieved 11 May 2020.
  67. Ross, Janet (1910). Lives of the early Medici as told in their correspondence. Chatto & Windus. p. 144.
  68. Blair, Iain (6 July 2011). "A Minute With: Bill Pullman about "Torchwood"". Reuters. Retrieved 30 July 2024.
  69. "Why Does Olivia Wilde's Fiancé Jason Sudeikis Think Her Cooking Always Tastes Good?". People. February 27, 2015. Archived from the original on January 25, 2016. Retrieved April 25, 2016. My fiancé [Jason Sudeikis] has no sense of smell — he was born without it....

Further reading